Shanghai Pharmaceuticals Holding Co Ltd (601607) - Net Assets

Latest as of March 2026: CN¥91.47 Billion CNY ≈ $13.38 Billion USD

Based on the latest financial reports, Shanghai Pharmaceuticals Holding Co Ltd (601607) has net assets worth CN¥91.47 Billion CNY (≈ $13.38 Billion USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥235.37 Billion ≈ $34.44 Billion USD) and total liabilities (CN¥143.90 Billion ≈ $21.06 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check how tangible is Shanghai Pharmaceuticals Holding Co Ltd's equity to evaluate the tangible quality of the company's equity base.

Key Net Assets Metrics

Metric	Value
Current Net Assets	CN¥91.47 Billion
% of Total Assets	38.86%
Annual Growth Rate	21.84%
5-Year Change	52.01%
10-Year Change	143.76%
Growth Volatility	77.48

Shanghai Pharmaceuticals Holding Co Ltd - Net Assets Trend (1994–2025)

This chart illustrates how Shanghai Pharmaceuticals Holding Co Ltd's net assets have evolved over time, based on quarterly financial data. See 601607 cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.

Annual Net Assets for Shanghai Pharmaceuticals Holding Co Ltd (1994–2025)

The table below shows the annual net assets of Shanghai Pharmaceuticals Holding Co Ltd from 1994 to 2025. For live valuation and market cap data, see Shanghai Pharmaceuticals Holding Co Ltd (601607) total market value.

Year	Net Assets	Change
2025-12-31	CN¥89.79 Billion ≈ $13.14 Billion	+7.22%
2024-12-31	CN¥83.74 Billion ≈ $12.25 Billion	+4.25%
2023-12-31	CN¥80.33 Billion ≈ $11.75 Billion	+2.98%
2022-12-31	CN¥78.00 Billion ≈ $11.41 Billion	+32.06%
2021-12-31	CN¥59.07 Billion ≈ $8.64 Billion	+7.90%
2020-12-31	CN¥54.74 Billion ≈ $8.01 Billion	+10.84%
2019-12-31	CN¥49.39 Billion ≈ $7.23 Billion	+6.36%
2018-12-31	CN¥46.43 Billion ≈ $6.79 Billion	+17.03%
2017-12-31	CN¥39.68 Billion ≈ $5.81 Billion	+7.71%
2016-12-31	CN¥36.83 Billion ≈ $5.39 Billion	+8.95%
2015-12-31	CN¥33.81 Billion ≈ $4.95 Billion	+8.71%
2014-12-31	CN¥31.10 Billion ≈ $4.55 Billion	+7.23%
2013-12-31	CN¥29.00 Billion ≈ $4.24 Billion	+4.69%
2012-12-31	CN¥27.70 Billion ≈ $4.05 Billion	+6.62%
2011-12-31	CN¥25.98 Billion ≈ $3.80 Billion	+118.62%
2010-12-31	CN¥11.88 Billion ≈ $1.74 Billion	+411.72%
2009-12-31	CN¥2.32 Billion ≈ $339.84 Million	+11.13%
2008-12-31	CN¥2.09 Billion ≈ $305.80 Million	+6.71%
2007-12-31	CN¥1.96 Billion ≈ $286.56 Million	-5.26%
2006-12-31	CN¥2.07 Billion ≈ $302.45 Million	+3.04%
2005-12-31	CN¥2.01 Billion ≈ $293.52 Million	-2.68%
2004-12-31	CN¥2.06 Billion ≈ $301.60 Million	-3.12%
2003-12-31	CN¥2.13 Billion ≈ $311.31 Million	+6.39%
2002-12-31	CN¥2.00 Billion ≈ $292.60 Million	+9.98%
2001-12-31	CN¥1.82 Billion ≈ $266.06 Million	+84.53%
2000-12-31	CN¥985.30 Million ≈ $144.18 Million	+15.93%
1999-12-31	CN¥849.92 Million ≈ $124.37 Million	+19.13%
1998-12-31	CN¥713.42 Million ≈ $104.40 Million	+149.80%
1997-12-31	CN¥285.60 Million ≈ $41.79 Million	+51.01%
1996-12-31	CN¥189.12 Million ≈ $27.67 Million	+3.37%
1995-12-31	CN¥182.95 Million ≈ $26.77 Million	-6.94%
1994-12-31	CN¥196.60 Million ≈ $28.77 Million	--

Equity Component Analysis

This analysis shows how different components contribute to Shanghai Pharmaceuticals Holding Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have grown by 246999.5% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2025)

Component	Amount	Percentage
Retained Earnings	CN¥40.72 Billion	53.66%
Other Components	CN¥35.17 Billion	46.34%
Total Equity	CN¥75.89 Billion	100.00%

Shanghai Pharmaceuticals Holding Co Ltd Competitors by Market Cap

The table below lists competitors of Shanghai Pharmaceuticals Holding Co Ltd ranked by their market capitalization.

Company	Market Cap
Noble Corporation plc NYSE:NE	$6.66 Billion
Osisko Gold Ro TO:OR	$6.67 Billion
Glaukos Corp NYSE:GKOS	$6.67 Billion
Cencosud SN:CENCOSUD	$6.68 Billion
Light & Wonder Inc NASDAQ:LNW	$6.65 Billion
Unicaja Banco SA MC:UNI	$6.65 Billion
InterDigital Inc NASDAQ:IDCC	$6.63 Billion
Bank of Maharashtra NSE:MAHABANK	$6.63 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Shanghai Pharmaceuticals Holding Co Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

From 2024 to 2025, total equity changed from 71,675,620,000 to 75,891,327,824, a change of 4,215,707,824 (5.9%).
Net income of 5,724,557,508 contributed positively to equity growth.
Dividend payments of 2,799,950,877 reduced retained earnings.
Other factors increased equity by 1,291,101,193.

Equity Change Factors (2024 to 2025)

Factor	Impact	Contribution
Net Income	CN¥5.72 Billion	+7.54%
Dividends Paid	CN¥2.80 Billion	-3.69%
Other Changes	CN¥1.29 Billion	+1.7%
Total Change	CN¥-	5.88%

Book Value vs Market Value Analysis

This analysis compares Shanghai Pharmaceuticals Holding Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 0.80x
The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
The price-to-book ratio has decreased from 40.42x to 0.80x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
1994-12-31	CN¥0.40	CN¥16.30	x
1995-12-31	CN¥0.38	CN¥16.30	x
1996-12-31	CN¥0.39	CN¥16.30	x
1997-12-31	CN¥0.59	CN¥16.30	x
1998-12-31	CN¥1.23	CN¥16.30	x
1999-12-31	CN¥1.29	CN¥16.30	x
2000-12-31	CN¥1.63	CN¥16.30	x
2001-12-31	CN¥3.09	CN¥16.30	x
2002-12-31	CN¥3.20	CN¥16.30	x
2003-12-31	CN¥3.55	CN¥16.30	x
2004-12-31	CN¥3.62	CN¥16.30	x
2005-12-31	CN¥3.61	CN¥16.30	x
2006-12-31	CN¥3.60	CN¥16.30	x
2007-12-31	CN¥2.87	CN¥16.30	x
2008-12-31	CN¥2.97	CN¥16.30	x
2009-12-31	CN¥0.92	CN¥16.30	x
2010-12-31	CN¥4.58	CN¥16.30	x
2011-12-31	CN¥9.53	CN¥16.30	x
2012-12-31	CN¥9.16	CN¥16.30	x
2013-12-31	CN¥9.65	CN¥16.30	x
2014-12-31	CN¥10.35	CN¥16.30	x
2015-12-31	CN¥11.13	CN¥16.30	x
2016-12-31	CN¥11.76	CN¥16.30	x
2017-12-31	CN¥12.66	CN¥16.30	x
2018-12-31	CN¥13.77	CN¥16.30	x
2019-12-31	CN¥14.66	CN¥16.30	x
2020-12-31	CN¥15.96	CN¥16.30	x
2021-12-31	CN¥17.37	CN¥16.30	x
2022-12-31	CN¥19.26	CN¥16.30	x
2023-12-31	CN¥18.51	CN¥16.30	x
2024-12-31	CN¥19.35	CN¥16.30	x
2025-12-31	CN¥20.46	CN¥16.30	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Shanghai Pharmaceuticals Holding Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): 7.54%
The company has moderate efficiency in generating returns from equity.
DuPont Analysis Breakdown:
• Net Profit Margin: 2.02%
• Asset Turnover: 1.22x
• Equity Multiplier: 3.07x
Recent ROE (7.54%) is below the historical average (9.22%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
1994	10.48%	8.54%	0.57x	2.15x	CN¥940.26K
1995	10.03%	5.44%	0.75x	2.46x	CN¥52.68K
1996	8.04%	4.74%	0.64x	2.65x	CN¥-3.70 Million
1997	10.04%	8.44%	0.57x	2.07x	CN¥126.97K
1998	13.17%	1.78%	1.69x	4.37x	CN¥18.94 Million
1999	15.04%	2.08%	1.48x	4.87x	CN¥31.65 Million
2000	23.28%	4.02%	1.30x	4.45x	CN¥105.43 Million
2001	9.65%	2.79%	1.21x	2.85x	CN¥-5.25 Million
2002	8.07%	1.74%	1.34x	3.46x	CN¥-30.11 Million
2003	8.93%	1.58%	1.59x	3.56x	CN¥-18.53 Million
2004	5.28%	0.86%	1.67x	3.67x	CN¥-83.19 Million
2005	2.87%	0.47%	1.68x	3.63x	CN¥-125.23 Million
2006	3.91%	0.60%	1.71x	3.80x	CN¥-106.84 Million
2007	4.04%	0.48%	1.95x	4.34x	CN¥-97.86 Million
2008	4.85%	0.50%	2.13x	4.59x	CN¥-86.92 Million
2009	9.45%	0.89%	2.26x	4.72x	CN¥-10.02 Million
2010	14.98%	3.66%	1.33x	3.08x	CN¥454.80 Million
2011	8.85%	3.72%	1.15x	2.07x	CN¥-265.61 Million
2012	8.33%	3.02%	1.33x	2.07x	CN¥-411.06 Million
2013	8.53%	2.83%	1.39x	2.17x	CN¥-381.80 Million
2014	9.31%	2.80%	1.44x	2.31x	CN¥-191.08 Million
2015	9.61%	2.73%	1.42x	2.48x	CN¥-116.04 Million
2016	10.11%	2.65%	1.46x	2.62x	CN¥34.14 Million
2017	10.35%	2.69%	1.39x	2.77x	CN¥117.56 Million
2018	9.95%	2.44%	1.25x	3.25x	CN¥-20.29 Million
2019	9.80%	2.19%	1.36x	3.29x	CN¥-84.91 Million
2020	9.91%	2.34%	1.29x	3.29x	CN¥-39.25 Million
2021	10.32%	2.36%	1.32x	3.31x	CN¥157.52 Million
2022	8.38%	2.42%	1.17x	2.95x	CN¥-1.09 Billion
2023	5.50%	1.45%	1.23x	3.09x	CN¥-3.08 Billion
2024	6.35%	1.65%	1.24x	3.09x	CN¥-2.62 Billion
2025	7.54%	2.02%	1.22x	3.07x	CN¥-1.86 Billion

Industry Comparison

This section compares Shanghai Pharmaceuticals Holding Co Ltd's net assets metrics with peer companies in the Medical Distribution industry.

Industry Context

Industry: Medical Distribution
Average net assets among peers: $11,181,681,676
Average return on equity (ROE) among peers: 10.20%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Shanghai Pharmaceuticals Holding Co Ltd (601607)	CN¥91.47 Billion	10.48%	1.57x	$6.65 Billion
China National Accord Medicines Corp Ltd (000028)	$13.91 Billion	8.71%	1.08x	$1.64 Billion
Shenzhen Glory Medical Co Ltd (002551)	$2.78 Billion	0.80%	0.40x	$378.59 Million
Shandong Realcan Pharmaceutical Co Ltd (002589)	$5.69 Billion	0.36%	1.81x	$631.94 Million
China National Accord Medicines Corp Ltd (200028)	$4.85 Billion	13.45%	1.64x	$125.06 Million
Qingdao Baheal Medical INC. (301015)	$2.17 Billion	19.39%	1.12x	$1.59 Billion
China Meheco Co Ltd (600056)	$12.22 Billion	10.73%	1.72x	$2.12 Billion
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd (600332)	$33.64 Billion	11.79%	1.22x	$4.44 Billion
China National Medicines Corp Ltd (600511)	$1.08 Billion	20.92%	1.56x	$3.00 Billion
Liaoning Cheng Da Co Ltd (600739)	$31.48 Billion	6.86%	0.53x	$2.36 Billion
Jointown Pharmaceutical Group Co Ltd (600998)	$4.00 Billion	8.99%	1.03x	$3.61 Billion

About Shanghai Pharmaceuticals Holding Co Ltd

SHG:601607 China Medical Distribution

Market Cap

$6.65 Billion

CN¥45.47 Billion CNY

Market Cap Rank

#2977 Global

#398 in China

Share Price

CN¥16.30

Change (1 day)

-1.21%

52-Week Range

CN¥16.18 - CN¥19.48

All Time High

CN¥25.03